However, validation in a second, independent series of metastatic CRC patients from the phase III FOCUS trial [13], treated with first-line FOLFIRI or 5-FU alone, did not confirm DCR1 methylation status as negative predictive marker for response to irinotecan-based therapy. Here, TNFRSF10C is linked to colorectal carcinoma.